Case Studies

Champions TumorGrafts® Guide the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496

Download Case Study

 

Using Champions’ patient-derived
xenograft (PDX) models for preclinical
validation of ERK pathway inhibitors

Download Case Study

 

Champions’ patient-derived xenograft (PDX) models for evaluating novel therapeutics targeting the DNA damage response mechanism

Download Case Study